Observation on the Clinical Efficacy of Amiodarone Combined with Irbesartan in the Treatment of Chronic Heart Failure with Paroxysmal Atrial Fibrillation

Objective:To investigate the effect,amiodarone combined with irbesartan treatment in chronic heart failure with paroxysmal atrial fibrillation.Methods:167 patients with chronic heart failure with paroxysmal atrial fibrillation used amiodarone to maintain sinus rhythm.All of the patients were divided into the treatment group and the control group according to whether using irbesartan.After one year,we observed that the hospitalization for heart failure rate,left ventricular ejection fraction,left atrial diameter,the rate of sinus rhythm maintenance and the rate of permanence atrial fibrillation.Results:After treatment,in the treatment group the rate of recurrence of atrial fibrillation and the incidence of chronic atrial fibrillation was significantly lower than the control group;in the treatment group sinus rhythm maintenance rate was significantly higher than the control group and left atrial diameter was significantly reduced compared with the control group;in the treatment group the rate of hospitalization for heart failure was significantly lower than the control group.All of them were significant differences(P0.05).There was expansion of the left atrial diameter compared with pretreatment in the control group(P0.05).Two groups of patients with cardiac function classification showed significant improvement compared with pre-treatment(P0.05) and between the two groups were no significant difference in heart function classification(P0.05).The adverse reactions of two groups(thyroid dysfunction,abnormal liver function,pulmonary fibrosis and hypotension) were no significant difference statistically(P0.05).Conclusion:The treatment with Amiodarone and irbesartan for chronic heart failure patients with paroxysmal atrial could maintain sinus rhythm,reduce the rate of hospitalization for heart failure,and have a better effect on myocardial remodeling and a good security.